Research
Hormonal
Intestinal GLP-1 from colonic L-cells is likely not involved in the acute control of meal size or thirst, but may play a role in long-term fluid balance and cardiovascular function.
The GLP-1 produced in your large intestine (colon) likely doesn't help you feel full or stop drinking during a meal. Its role is more about long-term fluid and heart health regulation, distinct from the GLP-1 produced in the small intestine which helps control appetite.
ModerateRefutesMEDIUM confidence
GLP-1 derived from them [colonic L-cells] is presumably not involved in the acute control of meal size... GLP-1 from colonic and rectal L-cells may be physiologically important for kidney and cardiovascular function but does not appear to play a role in the control of thirst by GLP-1
Why this rating
Based on the dynamics of gastrointestinal transit and lack of stimulation during meal-taking.
Source
Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Jean‐Philippe Krieger et al. · Comprehensive physiology · 2024
DOI 10.1002/cph4.7
narrative_reviewCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Endogenous peripheral GLP-1 enhances glucose-induced insulin release primarily through a vago-vagal reflex mediated by GLP-1 receptors on vagal sensory fibers, rather than through direct endocrine action on pancreatic beta-cells.Good
- Central GLP-1 produced by hindbrain PPG neurons and peripheral GLP-1 from intestinal L-cells regulate food intake through independent pathways, rather than acting synergistically or additively.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →